πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 50 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11623929

Spirocyclic compounds

C4 THERAPEUTICS, INC. Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11584748

Spirocyclic compounds

C4 THERAPEUTICS, INC. Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11459335

N/O-linked Degrons and Degronimers for protein degradation

C4 THERAPEUTICS, INC. Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11401256

Dihydroquinolinones for medical treatment

C4 THERAPEUTICS, INC. Β· Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11364300

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. Β· Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11185592

Spirocyclic degronimers for target protein degradation

C4 THERAPEUTICS, INC. Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11130746

Therapeutic compounds

C4X Discovery Limited Β· Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10980889

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10905768

Heterocyclic degronimers for target protein degradation

C4 THERAPEUTICS, INC. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10849982

C3-carbon linked glutarimide degronimers for target protein degradation

C4 THERAPEUTICS, INC. Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10696654

Therapeutic compounds

C4X Discovery Limited Β· Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10660968

Spirocyclic degronimers for target protein degradation

C4 THERAPEUTICS, INC. Β· Granted Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10646575

Heterocyclic degronimers for target protein degradation

C4 THERAPEUTICS, INC. Β· Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10611760

Therapeutic compounds as inhibitors of the orexin-1 receptor

C4X Discovery Limited Β· Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10428159

Blocking monoclonal antibodies to AGR2 and its receptor C4.4A

The Board of Regents of the University of Texas System Β· Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8835167

Humanized anti-tag 72 CC49 for diagnosis and therapy of human tumors

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8535890

Methods to determine immunogenicity of humanized anti-tag 72 CC49 antibodies

The United of America as represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Sep 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8513214

C4β€²-substituted-2-deoxyadenosine analogs and methods of treating HIV

The United States of America as represented by the Secretary of the Dept. of Health & Human Services Β· Granted Tue Aug 20 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8029788

Variants of humanized anti-carcinoma MAb CC49

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Oct 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7919607

Nucleic acids encoding humanized anti-tag 72 CC49 antbodies

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Apr 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7915396

Nucleic acid molecules encoding minimally immunogenic variants of SDR-grafted humanized an

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Mar 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7763719

Variants of humanized anti-carcinoma MAb CC49

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Jul 27 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7589181

Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Sep 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7569673

Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Aug 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted